Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 2
2007 1
2009 5
2010 5
2011 8
2012 13
2013 16
2014 9
2015 12
2016 11
2017 8
2018 17
2019 13
2020 16
2021 19
2022 24
2023 21
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

189 results

Results by year

Filters applied: . Clear all
Page 1
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, Jeon D, Lee T, Lee JY, Park JS, Lee SH, Kang YA, Lee JK, Kwak N, Ahn JH, Shim TS, Kim SY, Kim S, Kim K, Seok KH, Yoon S, Kim YR, Kim J, Yim D, Hahn S, Cho SN, Yim JJ; MDR-END investigators. Mok J, et al. Among authors: kang ya. Lancet. 2022 Oct 29;400(10362):1522-1530. doi: 10.1016/S0140-6736(22)01883-9. Lancet. 2022. PMID: 36522208 Clinical Trial.
Tuberculosis treatment in patients with comorbidities.
Kang YA. Kang YA. Tuberc Respir Dis (Seoul). 2014 Jun;76(6):257-60. doi: 10.4046/trd.2014.76.6.257. Epub 2014 Jun 28. Tuberc Respir Dis (Seoul). 2014. PMID: 25024718 Free PMC article. Review.
Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
Choi YH, Kang YA, Park KJ, Choi JC, Cho KG, Ko DY, Ahn JH, Lee B, Ahn E, Woo YJ, Jung K, Kim NY, Reese VA, Larsen SE, Baldwin SL, Reed SG, Coler RN, Lee H, Cho SN. Choi YH, et al. Among authors: kang ya. Infect Dis Ther. 2023 Jun;12(6):1605-1624. doi: 10.1007/s40121-023-00806-0. Epub 2023 May 11. Infect Dis Ther. 2023. PMID: 37166567 Free PMC article.
189 results